Effects of long-term statin-treatment on coronary atherosclerosis in patients with inflammatory joint diseases.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
15
02
2019
accepted:
26
11
2019
entrez:
13
12
2019
pubmed:
13
12
2019
medline:
27
3
2020
Statut:
epublish
Résumé
The effect of statins over time on coronary atherosclerosis in patients with inflammatory joint diseases (IJD) is unknown. Our aim was to evaluate the change in coronary plaque morphology and volume in long-term statin-treated patients with IJD. Sixty-eight patients with IJD and carotid artery plaque(s) underwent coronary computed tomography angiography before and after a mean of 4.7 (range 4.0-6.0) years of statin treatment. The treatment target for low density lipoprotein cholesterol (LDL-c) was ≤1.8 mmol/L. Changes in plaque volume (calcified, mixed/soft and total) and coronary artery calcification (CAC) from baseline to follow-up were assessed using the 17-segment American Heart Association-model. Median (IQR) increase in CAC after statin treatment was 38 (5-236) Agatston units (p<0.001). Calcified and total plaque volume increased with 5.6 (0.0-49.1) and 2.9 (0.0-23.5) mm3, respectively (p<0.001 for both). The median (IQR) change in soft/mixed plaque volume was -10 (-7.1-0.0), p = <0.001. Patients who had obtained the LDL-c treatment target at follow-up, experienced reduced progression of both CAC and total plaque volume compared to patients with LDL-c >1.8mmol/L (21 [2-143] vs. 69 [16-423], p = 0.006 and 0.65 [-1.0-13.9] vs. 13.0 [0.0-60.8] mm3, p = 0.019, respectively). A progression of total atherosclerotic plaque volume in statin-treated patients with IJD was observed. However, soft/mixed plaque volume was reduced, suggesting an alteration in plaque composition. Patients with recommended LDL-c levels at follow-up had reduced atherosclerotic progression compared to patients with LDL-c levels above the treatment target, suggesting a beneficial effect of treatment to guideline-recommended lipid targets in IJD patients.
Sections du résumé
BACKGROUND
The effect of statins over time on coronary atherosclerosis in patients with inflammatory joint diseases (IJD) is unknown. Our aim was to evaluate the change in coronary plaque morphology and volume in long-term statin-treated patients with IJD.
METHODS
Sixty-eight patients with IJD and carotid artery plaque(s) underwent coronary computed tomography angiography before and after a mean of 4.7 (range 4.0-6.0) years of statin treatment. The treatment target for low density lipoprotein cholesterol (LDL-c) was ≤1.8 mmol/L. Changes in plaque volume (calcified, mixed/soft and total) and coronary artery calcification (CAC) from baseline to follow-up were assessed using the 17-segment American Heart Association-model.
RESULTS
Median (IQR) increase in CAC after statin treatment was 38 (5-236) Agatston units (p<0.001). Calcified and total plaque volume increased with 5.6 (0.0-49.1) and 2.9 (0.0-23.5) mm3, respectively (p<0.001 for both). The median (IQR) change in soft/mixed plaque volume was -10 (-7.1-0.0), p = <0.001. Patients who had obtained the LDL-c treatment target at follow-up, experienced reduced progression of both CAC and total plaque volume compared to patients with LDL-c >1.8mmol/L (21 [2-143] vs. 69 [16-423], p = 0.006 and 0.65 [-1.0-13.9] vs. 13.0 [0.0-60.8] mm3, p = 0.019, respectively).
CONCLUSIONS
A progression of total atherosclerotic plaque volume in statin-treated patients with IJD was observed. However, soft/mixed plaque volume was reduced, suggesting an alteration in plaque composition. Patients with recommended LDL-c levels at follow-up had reduced atherosclerotic progression compared to patients with LDL-c levels above the treatment target, suggesting a beneficial effect of treatment to guideline-recommended lipid targets in IJD patients.
Identifiants
pubmed: 31830762
doi: 10.1371/journal.pone.0226479
pii: PONE-D-19-04035
pmc: PMC6908439
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0226479Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Circ Cardiovasc Imaging. 2016 Dec;9(12):
pubmed: 27956407
Int J Cardiol. 2015 Apr 1;184:581-6
pubmed: 25769003
Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):850-858
pubmed: 29617981
Ann Intern Med. 2015 Jul 7;163(1):14-21
pubmed: 26148276
JACC Cardiovasc Imaging. 2017 Apr;10(4):437-446
pubmed: 27771404
Circulation. 2003 Jan 28;107(3):363-9
pubmed: 12551853
Rheumatology (Oxford). 2014 Dec;53(12):2143-54
pubmed: 24907149
JAMA. 2007 Feb 7;297(5):499-508
pubmed: 17284700
Circulation. 2006 Jan 24;113(3):427-37
pubmed: 16415377
Circ J. 2009 Apr;73(4):718-25
pubmed: 19225206
JAMA. 2014 Jan 15;311(3):271-8
pubmed: 24247483
RMD Open. 2017 Sep 17;3(2):e000544
pubmed: 28955501
J Rheumatol. 2013 Apr;40(4):359-68
pubmed: 23322468
Ann Rheum Dis. 2010 Apr;69(4):683-8
pubmed: 19854705
Int J Cardiovasc Imaging. 2013 Jun;29(5):1177-90
pubmed: 23417447
Radiology. 2016 Dec;281(3):737-748
pubmed: 27636027
Eur Heart J. 2018 Jul 14;39(27):2551-2558
pubmed: 29688308
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
J Am Coll Cardiol. 2009 Jun 30;54(1):49-57
pubmed: 19555840
AJR Am J Roentgenol. 2014 Jan;202(1):W43-9
pubmed: 24370164
J Am Coll Cardiol. 2015 Apr 7;65(13):1283-1285
pubmed: 25835439
PLoS One. 2015 Jul 30;10(7):e0133433
pubmed: 26225936
Circulation. 2002 Aug 27;106(9):1077-82
pubmed: 12196332
Eur J Prev Cardiol. 2016 Dec;23(18):2007-2018
pubmed: 27638542
Circulation. 1975 Apr;51(4 Suppl):5-40
pubmed: 1116248
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Int J Cardiol. 2019 Jan 1;274:311-318
pubmed: 30007486
Cardiovasc Ultrasound. 2010 Mar 12;8:5
pubmed: 20226020
Eur J Epidemiol. 2007;22(4):235-43
pubmed: 17427036
J Am Coll Cardiol. 2013 Mar 26;61(12):1231-9
pubmed: 23500326
J Rheumatol. 2006 Nov;33(11):2167-72
pubmed: 16981296
Lancet. 2002 Jul 6;360(9326):7-22
pubmed: 12114036
Atherosclerosis. 2012 Nov;225(1):148-53
pubmed: 22981406
Eur Heart J. 2011 Mar;32(5):637-45
pubmed: 21037254
J Am Coll Cardiol. 2015 Apr 7;65(13):1273-1282
pubmed: 25835438
Cardiovasc Diagn Ther. 2016 Jun;6(3):250-8
pubmed: 27280088
Cardiovasc Res. 2014 Aug 1;103(3):341-9
pubmed: 24935434
Curr Cardiol Rev. 2017;13(3):209-216
pubmed: 28462692
Arthritis Rheumatol. 2015 Jul;67(7):1718-28
pubmed: 25778850
Eur J Radiol. 2013 Feb;82(2):264-9
pubmed: 23116807
Int J Cardiovasc Imaging. 2013 Jun;29(5):1095-104
pubmed: 23224377
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
pubmed: 27353126
Radiology. 2002 Jul;224(1):236-41
pubmed: 12091689
Atherosclerosis. 2013 Dec;231(2):198-204
pubmed: 24267226
Arthritis Rheum. 2012 Sep;64(9):2836-46
pubmed: 22576673
Int J Cardiovasc Imaging. 2010 Aug;26(6):711-20
pubmed: 20339922